Delivery Order SPE2DB22D3301-SPE2DB25FZ1PB
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $16,244.96 by the Defense Logistics Agency on September 17, 2025, for the supply of Ibrance 100 mg capsules (21-count packages). The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award. Performance will be completed at the contractor's Conshohocken facility by October 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Ibrance 75 mg tablets in quantities of seven units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $8,123.96 and is scheduled for completion by September 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents no set-aside designation....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 100 mg capsules (21-count) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which must be completed by September 16, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 22, 2025, for the supply of Ibrance 125 mg tablets (7-count units) valued at $16,236.16. The contract is a firm fixed-price delivery order with an ultimate completion date of October 14, 2025, and represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $8,118.08 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). This firm fixed-price, competitively awarded contract is scheduled for completion by October 20, 2025, and represents performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and is issued as a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ1PBDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 25, 2025, with a ceiling value of $16,236.16 for the supply of Ibrance 125 mg capsules (21-count packages). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 17, 2025, and was awarded on a competitive basis without set-aside restrictions. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The company's extensive portfolio of federal contract awards with the Defense Logistics Agency demonstrates its capability to deliver brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains. This delivery order for Ibrance, an oncology treatment, exemplifies the company's role in ensuring consistent pharmaceutical supply chain support for the Department of Defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/25/25 |